Elexacaftor/tezacaftor/ivacaftor and mental health: A workshop report from the Cystic Fibrosis Foundation's Prioritizing Research in Mental Health working group
Journal of Cystic Fibrosis · 2025-03 · 24 (2) · 301-309
DOI: 10.1016/j.jcf.2024.11.006 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cystic Fibrosis, 2025-03. Verfasst von C J Bathgate und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, National Jewish Health, Denver, CO, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Aminophenols, Quinolones, Benzodioxoles. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cystic Fibrosis Foundation.
Abstract (Originalsprache)
BACKGROUND: This report summarizes the 2023 inaugural annual meeting of the Cystic Fibrosis Foundation's Prioritizing Research in Mental Health (PRIME) working group. This workshop focused on mental health and elexacaftor/tezacaftor/ivacaftor (ETI). METHODS: We reviewed existing literature and identified key gaps and study design considerations in preclinical work, pharmacokinetics/pharmacodynamics, mood/anxiety, quality of life/self-perception, neuropsychological symptoms, sleep, and symptom management. RESULTS: Limited studies have identified behavioral changes with modulator exposure in rodent models of depression, anxiety, and cognition. Longitudinal human studies reporting mean changes generally show no change or improvement. However, case reports and single-center studies identify subgroups reporting new or worsening symptoms. CONCLUSIONS: Future studies should focus on understanding the role of CFTR in the nervous system, defining ETI impacts in preclinical models, and mechanistic investigations. Innovative methods with larger samples and comprehensive assessments are needed to determine the incidence of new/worsening symptoms throughout the lifespan and effective management strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, National Jewish Health, Denver, CO, USA.
- Center for Healthcare Delivery Science, Nemours Children's Health, Jacksonville, FL, USA.
- Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, IN, USA.
- Department of Biostatistics and Data Science, University of Kansas Medical Center, Kansas City, KS, USA.
- Department of Psychology, Virginia Commonwealth University, Richmond, VA, USA.
- Department of Physiological Sciences, University of Florida, Gainesville, FL, USA.
Förderung
- Cystic Fibrosis Foundation
Zitieren
APA
Bathgate, C. J., Fedele, D. A., Tillman, E. M., He, J., Everhart, R. S., Reznikov, L. R., Liu, F. F., Kirby, K., Raffensperger, K., Traver, K., Riekert, K. A., Powers, S. W., & Georgiopoulos, A. M. (2025). Elexacaftor/tezacaftor/ivacaftor and mental health: A workshop report from the Cystic Fibrosis Foundation's Prioritizing Research in Mental Health working group. Journal of Cystic Fibrosis, 24(2), 301-309. https://doi.org/10.1016/j.jcf.2024.11.006
Vancouver
Bathgate CJ, Fedele DA, Tillman EM, He J, Everhart RS, Reznikov LR, et al. Elexacaftor/tezacaftor/ivacaftor and mental health: A workshop report from the Cystic Fibrosis Foundation's Prioritizing Research in Mental Health working group. Journal of Cystic Fibrosis. 2025;24(2):301-309. doi:10.1016/j.jcf.2024.11.006
BibTeX
@article{Bathgate2025,
author = {Bathgate, C J and Fedele, D A and Tillman, E M and He, J and Everhart, R S and Reznikov, L R and Liu, F F and Kirby, K and Raffensperger, K and Traver, K and Riekert, K A and Powers, S W and Georgiopoulos, A M},
title = {Elexacaftor/tezacaftor/ivacaftor and mental health: A workshop report from the Cystic Fibrosis Foundation's Prioritizing Research in Mental Health working group},
journal = {Journal of Cystic Fibrosis},
year = {2025},
volume = {24},
number = {2},
pages = {301--309},
doi = {10.1016/j.jcf.2024.11.006}
}
EUVIMED